TY  - BOOK
AU  - Sefrioui,David
AU  -  Grancher,Adrien
AU  -  Di Fiore,Frédéric
TI  - Circulating tumor DNA and colorectal cancer: From bench to bedside
PY  - 2022///.
							
N1  - 98
N2  - Circulating tumor DNA (ctDNA) are fragments of DNA released by tumor cells into the bloodstream. More than 6,000 articles have been devoted to this biomarker over the past ten years, including nearly 1,000 about colorectal cancer (CRC). This renewed interest has been sparked in particular by a better understanding of the pathophysiology of this biomarker and the advent of the technological progress necessary for its detection. The rationale for the use of ctDNA is indeed considerable since this “liquid biopsy” makes it possible to study a wide range of genetic alterations in a rapid and non-invasive way. This liquid biopsy also offers the advantages of being able to be repeated over time and representing the neoplastic spatio-temporal heterogeneity. In this context, ctDNA is positioned as an ideal candidate biomarker that could be used at each stage of the oncology care pathway. Numerous studies have thus shown the potential interest of ctDNA in many areas such as screening, prognostic tools, and the detection of residual disease or genetic alterations predictive of treatment efficacy. The current challenge over the coming years will concern the routine integration of this biomarker to adapt the care of our patients. The results of interventional studies using this biomarker as a decision-making tool for therapeutic strategy are eagerly awaited. The aim of this review is to provide an overview of knowledge about ctDNA in CRC in terms of detection conditions and its main clinical applications
UR  - https://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-6-page-741?lang=en
ER  -